{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:26:12Z","timestamp":1789691172576,"version":"4.0.1"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T00:00:00Z","timestamp":1261440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Nodular, lymphocyte\u2010predominant Hodgkin lymphoma (NLPHL) represents a rare entity.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>A clinical registry was launched from 1973 to 2003 in France. To determine the histologic transformation (HT) rate to diffuse large B\u2010cell lymphoma (DLBCL) and long\u2010term outcomes, 164 patients were selected after histologic review.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>The median follow\u2010up was 9.5 years. The high biopsy rate (85%) at each recurrence enabled the analysis of HT. The median patient age was 30 years (range, 6\u201069 years), 80% of patients were men, 83% had Ann Arbor stage I\/II disease, 65% had supradiaphragmatic\u2010disease; 27% received radiotherapy, 9% received chemotherapy, 29% received combined\u2010modality therapy, and 35% were followed with a watch\u2010and\u2010wait strategy. All 106 treated patients achieved complete remission and 66 patients developed disease recurrence at a median of 3.3 years (range, 0.4\u201018.3 years after diagnosis). The majority of recurrences were NLPHL, but 19 patients progressed to DLBCL at a median of 4.7 years (range, 0.4\u201018 years after diagnosis). The 10\u2010year cumulative HT rate was 12% and was found to be associated significantly with a poor prognosis. The 10\u2010year overall survival rate was 91%. Fourteen patients died (7 died of progressive disease, 3 died of secondary cancers, and 4 died from other causes). HT was diagnosed at a median of 4.7 years (range, 0.4\u201018 years after diagnosis). The 19 patients who had HT were treated with curative intent: Nine patients received high\u2010dose therapy with subsequent autologous stem cell transplantation (ASCT), and 10 patients received different chemotherapy regimens. The overall survival rate after HT did not differ between patients who underwent ASCT and the others.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>This long\u2010term follow\u2010up study confirmed that NLPHL is a separate entity that has a favorable clinical presentation and outcome despite frequent recurrences. The current findings also emphasize the importance of biopsies at the time patients develop recurrent disease to evaluate HT. Cancer 2010. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24819","type":"journal-article","created":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T13:41:53Z","timestamp":1261489313000},"page":"631-639","source":"Crossref","is-referenced-by-count":159,"title":["Nodular, lymphocyte\u2010predominant Hodgkin lymphoma"],"prefix":"10.1002","volume":"116","author":[{"given":"Irene","family":"Biasoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Stamatoullas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Meignin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Delmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumedaly","family":"Reman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Bosly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Divin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_6_3_2","first-page":"1","article-title":"Hodgkin's disease, lymphocyte predominance type, nodular\u2014a distinct entity? Unique staining profile for L&H variants of Reed\u2010Sternberg cells defined by monoclonal antibodies to leukocyte common antigen, granulocyte\u2010specific antigen, and B\u2010cell\u2010specific antigen","volume":"118","author":"Pinkus GS","year":"1985","journal-title":"Am J Pathol."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198801283180404"},{"key":"e_1_2_6_5_2","first-page":"19","article-title":"[Hodgkin disease with nodular lymphocytic predominance or type I (paragranuloma of Poppema\u2010Lennert): a clinico\u2010pathological entity. Study of 21 cases and review of the literature.]","volume":"20","author":"Meignin V","year":"2000","journal-title":"Ann Pathol."},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.V87.6.2428.bloodjournal8762428","article-title":"Nodular lymphocyte predominance Hodgkin's disease: a monoclonal or polyclonal B\u2010cell disorder?","volume":"87","author":"Pan LX","year":"1996","journal-title":"Blood."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.657.bloodjournal882657"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1592"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/2.suppl_2.83"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709051786"},{"key":"e_1_2_6_11_2","first-page":"1431","article-title":"The importance of follow\u2010up biopsies of clinically suspicious lymphadenopathy in nodular lymphocyte predominant Hodgkin's lymphoma","volume":"88","author":"Achten R","year":"2003","journal-title":"Haematologica."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06736.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0567"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8869"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2644"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.079"},{"key":"e_1_2_6_17_2","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.776"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.2.239"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1331"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi323"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21303"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3060"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000123528"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22762"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078725"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24819","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:58:35Z","timestamp":1760302715000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24819"}},"subtitle":["A long\u2010term study and analysis of transformation to diffuse large B\u2010cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group"],"short-title":[],"issued":{"date-parts":[[2009,12,22]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1002\/cncr.24819"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24819","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,22]]}}}